Nurix Therapeutics (NRIX) Shares Outstanding (Weighted Average) (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Shares Outstanding (Weighted Average) data on file, last reported at $110.1 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $110.1 million, up 31.73% year-over-year; the trailing twelve-month figure through Feb 2026 was $110.1 million (up 31.73% YoY), and the FY2025 annual result was $86.7 million, up 29.12% from the prior year.
• Shares Outstanding (Weighted Average) improved to $110.1 million in Q1 2026 per NRIX's latest filing, from $86.7 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $110.1 million in Q1 2026 and troughed at $44.7 million in Q1 2022.
• A 5-year average of $65.2 million and a median of $54.9 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) grew 1.62% in 2024, then jumped 52.2% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $48.6 million in 2022, then advanced by 11.79% to $54.3 million in 2023, then climbed by 23.52% to $67.1 million in 2024, then advanced by 29.12% to $86.7 million in 2025, then climbed by 27.01% to $110.1 million in 2026.
• Business Quant data shows NRIX's Shares Outstanding (Weighted Average) at $110.1 million in Q1 2026, $86.7 million in Q4 2025, and $83.9 million in Q3 2025.